Aeon Bioscience Continues Development of Drug Elut... ( BIRMINGHAM Ala. Oct. 10 -- Aeon ...)

Aeon Bioscience Continues Development of Drug Eluting Stents

Date:10/10/2007

BIRMINGHAM, Ala., Oct. 10 /PRNewswire-USNewswire/ -- Aeon Bioscience, Inc. today announced the recent acquisition of one of its key collaborators, Brookwood Pharmaceuticals, Inc. by SurModics, Inc., a major development in its quest to develop improvements in drug-eluting stent technology for the treatment of cardiovascular disease.

Aeon Bioscience was formed as a collaborative enterprise between Brookwood Pharmaceuticals, Inc. and Targeted Technology Ventures, LLC. Subsequent to announcing the collaboration on May 7, 2007, Brookwood was acquired on August 1, 2007 by SurModics, Inc., a leading provider of surface modification and drug delivery technologies to the healthcare industry. As a result of this acquisition, Aeon expects to benefit from SurModics' experience in developing drug delivery technologies for drug eluting stents.

Christopher E. Banas, Principal of Targeted Technology Ventures and CEO of Aeon Bioscience, said "The combined strengths of Brookwood and TTV have supplied Aeon with superior experience and talent in the use of biodegradable materials, drug delivery, vascular stent engineering, clinical testing, and the regulatory process. The addition of the SurModics team facilitates our ability to advance our technology to an even higher level, and at an accelerated pace, as we work to achieve our objective of developing a solution to the safety issues currently experienced with drug eluting stents." Dr. Paul Castella, Principal of TTV and co-founder of Aeon agrees, "We have an exceptional operating team, a renowned advisory board of international leaders in the field, and now a prominent set of added capabilities."

Dr. Arthur J. Tipton, Ph.D., President of Brookwood Pharmaceuticals, added "We remain excited about the opportunity presented by the Aeon technology. This collaboration will substantially benefit from the vast experience and expertise that the SurModics organization has accumulated in the cardiovascular market." '/>"/>

SOURCE Aeon Bioscience
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. OxyContin Abuse Continues To Rise
2. Alzheimer’s Continues to Ris
3. Uttar Pradesh Encephalitis toll continues to rise - Over 600 dead
4. Human Brain Continues To Evolve And Grow
5. War Against Cancer Continues
6. Botswana Continues Its Fight Against AIDS
7. US Continues Its War On Diabetes
8. Polio Continues To Haunt India
9. Reservation boycott by Medical student fraternity continues in Bangalore
10. Patients Left Helpless As Mumbai Doctors Strike Continues
11. Health Services Came To A Halt As Mumbai Doctors Strike Continues

Post Your Comments:

(Date:5/23/2013)... have shown that an immune regulatory molecule called IL-21 ... viral infections. , The results are published in the ... how IL-21 could be important in the development of ... PhD, the first author of the paper. The senior ... Vaccine Center and a Georgia Research Alliance Eminent Scholar. ...

(Date:5/23/2013)... Netsmart today announced it is ranked ... information technology (HIT) providers for 2013. , The HCI 100 ... Healthcare Informatics magazine. Netsmart’s ranking of #49 is up ... growth is largely due to our commitment to helping organizations ... where resources are scarce, the demand for care is unprecedented ...

(Date:5/23/2013)... patients over the past two decades have found ... of new therapies, overall mortality has decreased and ... of severe abnormal heart rhythms, has declined. ... today, with these significant improvements, one-third of patients ... diagnosed with advanced disease. Heart failure is increasingly ...

(Date:5/23/2013)... (PRWEB) May 23, 2013 Elegance for a woman ... her flair, her taste, her intrigue can often be found in ... gateway to a woman's soul is through her eyes. It ... who she is! That is why the elegance of a woman ... . , Women today, more than any other time, utilize eyewear ...

(Date:5/23/2013)... 2013 A new report ... Medicaid program could save $2.1 billion without reducing access ... report shows that Florida and other state Medicaid programs ... and employers rely on to curb wasteful pharmacy spending. ... pharmacy at MedicaidPharmacySavings.com . , “The easiest way ...

Breaking Medicine News(10 mins):Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2 Health News:Netsmart Named to Healthcare Informatics Top 100 List 2 Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 2 Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 3 Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2 Health News:PCMA: Upgrading Medicaid Drug Benefits Could Save Florida $2.1 Billion 2

[0] Vaccine blackjack: IL-21 critical to fight against viral infections [0] Netsmart Named to Healthcare Informatics Top 100 List [0] Death rates decline for advanced heart failure patients, but outcomes are still not ideal [0] Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc.[0] PCMA: Upgrading Medicaid Drug Benefits Could Save Florida $2.1 Billion

... Eating Tips to Stay Balanced Through the ... ... Registered dietitian, celebrity,chef, and New York Times best-selling author Ellie Krieger, ... the benefits of,digestive health. Yo-Plus contains live and active probiotic cultures,specifically ...

... N.C., Nov. 5 Cornerstone Therapeutics,Inc. (Nasdaq ... on,developing and commercializing prescription medications for respiratory,disorders, ... of the recently,completed merger between Cornerstone BioPharma ... Collard, 42, president and chief executive,officer and ...

... 5 CardiacAssist, Inc. announced that,it reached a new high ... least one TandemHeart case during the third quarter of 2008.,In ... on,year growth in case activity with a leap of 64 ... and 497 %. Through nine months of 2008,CardiacAssist has also ...

... Corporate Highlights:, -- Net service revenues increased 84% to $58.7 ... to $48.6 million -- Net income increased 149% to $4.7 ... share on 49% more shares -- Completed acquisition of Patient ... 200 Best Small Companies List, Almost Family, Inc. (Nasdaq: ...

... to ... 9-hour flights, HOBOKEN, N.J., Nov. 5 ... pine bark,extract from the French maritime pine tree, reduces jetlag in passengers ... and a,scoring system, showed Pycnogenol(R) lowered symptoms of jetlag such as,fatigue, headaches, ...

... Nov. 5 CuraGen Corporation,(Nasdaq: CRGN ), a ... Timothy M. Shannon, President and Chief,Executive Officer, will present ... Investment Conference on Wednesday, November 12, 2008, at,3:15 p.m. ... New York Palace,Hotel in New York, NY., Access ...

Healthy Eating Expert Ellie Krieger Joins Yoplait(R) Yo-Plus(TM) to Raise Awareness of Digestive Health Cornerstone Therapeutics Announces New Board of Directors CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results Almost Family Reports Third Quarter 2008 Results Study Shows Pine Bark Reduces Jetlag CuraGen to Present at the Rodman & Renshaw Annual Global Investment Conference

(Date:5/23/2013)... -- Echo Pharma Acquisition Limited ("Royalty Pharma") announced today that ... from 90 percent to 50 percent of Maximum Elan ... the terms of the Revised Offer Document issued today, ... the terms of the Increased Offer, Royalty Pharma is ... for $12.50 per share in cash. The Increased Offer ...

(Date:5/23/2013)... , May 23, 2013 BioLife Solutions , ... proprietary clinical grade hypothermic storage and ... contract aseptic media manufacturer , today announced its ... Regenerative Medicine Congress 2013 this week in ... ) Dr. Aby J. Mathew, BioLife,s Senior ...

(Date:5/23/2013)... and PARIS , May ... ), a leading developer and manufacturer of precision guided ... of coronary and peripheral vascular disease, today announced preliminary ... asodilator I ndependent S tenosis E ... clinical trial session at EuroPCR 2013. These prospective results ...

Breaking Medicine Technology:Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5

[0] Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share [0] BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress [0] Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013

... A leader in healthcare, Henry Ford Health System will ... representing a "breakthrough" designed to improve treatment outcomes and ... admissions due to poor medication management by patients. ... programmable timers with Rexam prescription vials, which give audio ...

... BIOD ) today announced that it has entered into ... of its common stock and warrants to purchase 2,398,200 shares ... being sold as units, with each unit consisting of one ... share of common stock. The investors have ...

Cached Medicine Technology:Pharmacovigilance Breakthrough: Henry Ford Health System Partners with Rexam and Med Time Technology to Remind Patients to Take Prescription Medication "As Prescribed" to reduce $300 Billion National Healthcare Problem 2 Biodel to Raise $9.4 Million Through Registered Direct Offering 2 Biodel to Raise $9.4 Million Through Registered Direct Offering 3

Pharmacovigilance Breakthrough: Henry Ford Health System Partners with Rexam and Med Time Technology to Remind Patients to Take Prescription Medication "As Prescribed" to reduce $300 Billion National Healthcare Problem Biodel to Raise $9.4 Million Through Registered Direct Offering

Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With Tubular Base....

Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....

... an independent laboratory to ... of Federal Standard 209E. ... confort, reduces fatique and ... meets Class 100 particle ...

Medicine Products:

4V62 4V42-R 4V41-R Class 100 Chair